Study summary

AMX0035 showed no benefit in PSP, and the trial was stopped

ORION trial (AMX0035) · Phase 2b/3, interim analysis · Announced August 2025

What was tested

AMX0035 (sodium phenylbutyrate and taurursodiol), a combination pill aimed at protecting nerve cells, against placebo, in a phase 2b/3 trial in PSP.

What they found

What it means

One of several setbacks that have pushed the field toward drugs that target tau directly.

CurePSP ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.